It has been demonstrated that gastrointestinal extracts contain substances which react immunologically with antibodies prepared to pancreatic glucagon. These extracts have been termed intestinal GLI for glucagon-like immunoreactivity, or enteroglucagon. To determine whether GLI has specific biological effects, studies were designed using the criterion of effect with antiglucagon antibodies. These antibodies did not cross-react with either secretin or pancreozymin.
Raul A. Gutman, Gloria Fink, Nancy Voyles, Helena Selawry, Juan C. Penhos, Albert Lepp, Lillian Recant
Usage data is cumulative from April 2024 through April 2025.
Usage | JCI | PMC |
---|---|---|
Text version | 108 | 3 |
47 | 13 | |
Scanned page | 415 | 6 |
Citation downloads | 46 | 0 |
Totals | 616 | 22 |
Total Views | 638 |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.